Ketamine Tablet: Complete Overview

Ketamine tablet uses center on off-label maintenance therapy for treatment-resistant depression, anxiety disorders, PTSD, and chronic pain conditions such as neuropathy and complex regional pain syndrome. Oral ketamine is compounded into tablets, troches, capsules, or liquid solutions and is typically introduced after a patient has already responded to intravenous or intramuscular ketamine, since low gastrointestinal bioavailability makes the oral route better suited to sustaining a response than inducing one from scratch. This overview covers the available forms of ketamine tablet, the pharmacology behind its low bioavailability, its clinical history, current uses, and its regulatory status so patients and clinicians can evaluate it as a treatment option.

What Is Ketamine Tablet?

Ketamine is a dissociative anesthetic, a drug that produces pain relief and altered sensory perception while the patient can remain partially conscious. It was developed in the 1960s and approved by the FDA for anesthetic use in 1970 under the brand name Ketalar, according to StatPearls. When taken orally, ketamine passes through the gastrointestinal tract and liver before reaching the bloodstream, a route governed by first-pass metabolism, the process by which the liver breaks down a substantial portion of an ingested drug before it can act on the rest of the body. That process is central to how oral ketamine tablet uses differ from IV ketamine, and it also produces norketamine, an active metabolite that may contribute to the drug's antidepressant and pain-relieving effects.

Clinicians prescribe ketamine tablet off-label, meaning outside the conditions the FDA specifically approved, for a growing list of psychiatric and pain conditions, most notably treatment-resistant depression, anxiety disorders, PTSD, and chronic pain syndromes.

Forms of Ketamine Tablet

Ketamine tablet uses depend partly on which oral formulation a prescriber selects, since each form has different absorption characteristics.

Tablets

Pharmaceutical-grade ketamine tablets are compounded or manufactured in fixed doses and swallowed whole. They pass through the digestive system before absorption, provide consistent dosing, and are easy to store and administer.

Troches (Buccal Lozenges)

Troches dissolve slowly in the mouth, allowing some absorption through the buccal mucosa, the lining of the cheeks and gums. This partially bypasses first-pass liver metabolism, giving troches slightly higher bioavailability than swallowed tablets. See our guide to ketamine troches for a closer comparison of the two forms.

Oral Solutions

Compounding pharmacies can prepare liquid ketamine for oral use. Solutions allow flexible dosing adjustments but require careful measurement to avoid dosing errors.

Capsules

Capsules filled with ketamine powder are another compounded option. Like tablets, they are swallowed and subject to full first-pass hepatic metabolism.

Bioavailability: The Core Challenge

Bioavailability is the percentage of an administered drug dose that reaches systemic circulation in active form. It is the single biggest factor separating ketamine tablet uses from IV ketamine therapy. When ketamine is taken orally, typically only 10 to 25 percent of the dose reaches systemic circulation, according to StatPearls. Intravenous ketamine, by comparison, achieves close to 100 percent bioavailability, and intramuscular ketamine reaches 90 to 95 percent. Sublingual and intranasal routes fall in between, at roughly 25 to 50 percent each.

Because so much of an oral dose is lost to first-pass metabolism, oral doses must be significantly higher than IV doses to reach comparable plasma levels. A patient receiving 0.5 mg per kg IV might need an oral dose in the range of 3 to 6 mg per kg to approximate similar drug exposure, though oral maintenance therapy is often dosed lower and targets a different therapeutic window than acute IV treatment. For a direct side-by-side look at how the two routes compare in practice, see our oral vs. IV ketamine comparison.

Clinical History

Ketamine tablet use traces back to the 1990s, when pain specialists began using oral ketamine for chronic pain management. Palliative care practitioners were among the earliest adopters, using it to manage refractory cancer pain when intravenous access was impractical.

In the early 2000s, as research on ketamine's rapid antidepressant effects accumulated, psychiatrists began exploring oral formulations for depression. The appeal was straightforward: oral administration at home could potentially help maintain the antidepressant response achieved during IV treatment, without requiring repeated infusion visits. For more on how these formulations developed, see our history of ketamine tablets.

Current Clinical Uses

Psychiatric Applications

• Treatment-resistant depression (TRD): patients who have not responded to multiple antidepressant trials may be prescribed ketamine tablet, particularly as maintenance therapy after IV induction. See our coverage of ketamine tablets and TRD remission for recent findings.
• Anxiety disorders: generalized anxiety disorder, social anxiety, and panic disorder are areas of ongoing research
• PTSD: some treatment protocols use ketamine tablet as part of a broader trauma treatment program
• OCD: preliminary research suggests that ketamine's effect on glutamate signaling may benefit some patients with OCD

Pain Applications

• Complex regional pain syndrome (CRPS): low-dose ketamine tablet may help reduce central sensitization
• Neuropathic pain, including diabetic neuropathy and postherpetic neuralgia
• Fibromyalgia: some patients report benefit from low chronic doses
• Palliative and cancer pain: ketamine tablet remains used for refractory pain in terminal illness

Perioperative Use

Some surgical centers use ketamine tablet before surgery to reduce anxiety and lower postoperative opioid requirements.

Depression remains one of the most common reasons ketamine tablet is prescribed off-label. According to the World Health Organization, depression affects an estimated 5 percent of adults worldwide, making it one of the leading causes of disability globally and a major driver of demand for treatments like ketamine that work through mechanisms different from standard antidepressants.

Regulatory Status

Ketamine itself is FDA-approved as an anesthetic under the brand name Ketalar. Every psychiatric and pain use of ketamine tablet described above is off-label, meaning the FDA has not specifically evaluated or approved oral ketamine for those conditions. Off-label prescribing is legal and common across medicine, but it means the evidence base and dosing conventions rely on clinical literature and practitioner experience rather than an FDA-reviewed indication.

Ketamine tablet is primarily accessed through compounding pharmacies operating under a physician's prescription, or through some 503B outsourcing facilities that produce larger batches under stricter FDA oversight than traditional compounding pharmacies. The FDA classifies ketamine as a Schedule III controlled substance, which means prescribers must follow DEA requirements for controlled substance prescribing, including limits on refills and record-keeping. Because oral ketamine is compounded rather than commercially manufactured for these indications, insurance coverage is inconsistent; our article on the insurance coverage gap for oral ketamine tablets covers what that means for patient access.

The Role of Ketamine Tablet Today

Ketamine tablet occupies a specific niche in the treatment landscape. It produces a milder acute effect than IV infusion, but it is more accessible, generally more affordable, and more practical for long-term maintenance therapy between in-clinic treatments. As compounding regulations evolve and more clinical research accumulates, oral formulations are likely to become a more formalized part of psychiatric and pain treatment protocols. Patients considering ketamine tablet should discuss dosing, monitoring, and realistic expectations with a prescriber experienced in its use, since off-label status means treatment plans vary by clinic and by patient.